Kháng thể người có nguồn gốc từ nhiễm SARS-CoV-2 ban đầu trung hòa hiệu quả biến thể Omicron

Advanced Biotechnology
Tingting Li1, Bingjie Zhou2, Huafeng Dong3, Dimitri Lavillette3, Dianfan Li1
1Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200030, China
2Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200030, China
3Pasteurien College, Soochow University, Jiangsu, China

Tóm tắt

Tóm tắtBiến thể đáng lo ngại (Variants of Concern - VOCs) của SARS-CoV-2 (Virus corona gây hội chứng hô hấp cấp tính nghiêm trọng 2), chẳng hạn như các biến thể phụ Omicron, đặt ra những thách thức lớn trong việc kiểm soát đại dịch do khả năng của chúng trong việc thoát khỏi kháng thể và vượt qua mức bảo vệ của vắc xin. Việc phát hiện ra các kháng thể có khả năng dung nạp sự đột biến trong các VOC và hiểu rõ các cơ chế bên dưới là rất quan trọng cho sự phát triển các liệu pháp điều trị cho bệnh nhân COVID-19, đặc biệt là đối với những bệnh nhân mà các liệu pháp khác có thể không phù hợp. Trong nghiên cứu này, chúng tôi báo cáo việc trung hòa biến thể Omicron bởi FD20, một kháng thể đơn dòng của con người hoạt động mạnh mẽ. Khác với một kháng thể đối chứng được phê duyệt lâm sàng, FD20 trung hòa Omicron với giá trị IC50 tương đương với những gì được quan sát cho các VOC đã lưu hành trước đó và chủng gốc được báo cáo tại Vũ Hán. Tận dụng thông tin cấu trúc, chúng tôi cung cấp cái nhìn sâu sắc về khả năng chịu đựng đột biến của kháng thể này trong biến thể Omicron. Kết quả khuyến khích việc phát triển FD20 như một lựa chọn điều trị cho COVID-19 do các VOC hiện tại và có thể xảy ra trong tương lai gây ra.

Từ khóa


Tài liệu tham khảo

Barnes CO, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588:682–7.

Barnes CO, et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell. 2020;182:828–42 e16.

Brouwer PJM, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369:643–50.

Cameroni E, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022;602:664–70.

Cao Y, et al. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells. Cell. 2020;182:73–84 e16.

Cao Y, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657–63.

Chen RE, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27:717–26.

Cui Z, et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell. 2022;185:860–71 e13.

Dejnirattisai W, et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell. 2021;184:2183–200 e22.

Greaney AJ, et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe. 2021;29:44–57 e9.

Hansen J, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369:1010–4.

Hastie KM, et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science. 2021;374:472–8.

Henderson R, et al. Controlling the SARS-CoV-2 spike glycoprotein conformation. Nat Struct Mol Biol. 2020;27:925–33.

Hoffmann M, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271–280.e8.

Huo J, et al. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell Host Microbe. 2020;28:445–54 e6.

Iketani S, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604:553–6.

Lan J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–20.

Li T, et al. Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody. EMBO Mol Med. 2021a;13: e14544.

Li T, et al. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. Nat Commun. 2021b;12:4635.

Li T, et al. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. Nat Commun. 2021c;12:4635.

Li T, et al. Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2. Int J Biol Macromol. 2022a;209:1379–88.

Li T, et al. Structural Characterization of a Neutralizing Nanobody With Broad Activity Against SARS-CoV-2 Variants. Front Microbiol. 2022b;13: 875840.

Liu H, et al. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity. 2020;53:1272–80 e5.

Liu L, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602:676–81.

Liu, Z. et al. An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. Protein Cell (2021).

Lv Z, et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020;369:1505–9.

McCallum M, et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science. 2022;375:864–8.

Meng L, et al. A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy. PLoS Pathog. 2023;19: e1011085.

Nabel, K.G. et al. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Science 375, eabl6251 (2022).

Piccoli L, et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020;183:1024–42 e21.

Planas D, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671–5.

Schoof M, et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020;370:1473–9.

Shang J, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117:11727–34.

Sheward, D.J. et al. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. Lancet Infect Dis (2022).

Shi R, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584:120–4.

Starr TN, et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell. 2020;182:1295–310 e20.

Starr TN, et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature. 2021;597:97–102.

Tuekprakhon A, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185:2422–2433. e13.

VanBlargan LA, et al. An infectious SARS-CoV-2 B.1.1.529Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022;28:490–5.

Walls AC, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181:281–292.e6.

Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020;369:330–3.

Wrapp D, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–3.

Yamin R, et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature. 2021;599:465–70.

Yao H, et al. A high-affinity RBD-targeting nanobody improves fusion partner’s potency against SARS-CoV-2. PLoS Pathog. 2021;17:e1009328.

Zhou D, et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol. 2020;27:950–8.

Thông tin
Thông tin xuất bản

Advanced Biotechnology

Thông tin tác giả